NEU 6.41% $15.27 neuren pharmaceuticals limited

Share Price, page-2321

  1. 3,313 Posts.
    lightbulb Created with Sketch. 7334
    Or maybe, he has price sensitive information that hasn’t been released to the market as yet. In which case Ho would stop trading and commenting on NEU.

    It does happen where directors and CEO’s sometimes asked advice or opinions from large shareholders!

    At this point in time NEU would be very well aware of the value for a ROW deal. They have been in negotiations for over 18 months. It’s now getting the best option for shareholders and doing the extensive paperwork.

    They have also mentioned that they have had approaches to discuss the opportunity to explore AUTISM from some business g Pharma!

    So it is highly likely they also have a good idea of what a takeover bid woukd look like. So a question around what shareholders would expect from a takeover is something a BOD woukd like to know if they are in deep negotiations.

    I remember one chairman asking my thoughts on a Cap Raise. I suggest 2 times what they eventually went for. He told me later he thought I was over optimistic, but the raise was heavily oversubscribed. He just need some shareholders to help him gain some perspective.

    All the silence lately tells me we have news coming soon. Good news.
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.